Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial

Zelniker, 2019, SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials, Lancet, 393, 31, 10.1016/S0140-6736(18)32590-X Zannad, 2020, SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials, Lancet, 396, 819, 10.1016/S0140-6736(20)31824-9 Heerspink, 2020, Dapagliflozin in patients with chronic kidney disease, N Engl J Med, 383, 1436, 10.1056/NEJMoa2024816 Hallow, 2018, Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis, Diabetes Obes Metab, 20, 479, 10.1111/dom.13126 Griffin, 2020, Empagliflozin in heart failure: diuretic and cardiorenal effects, Circulation, 142, 1028, 10.1161/CIRCULATIONAHA.120.045691 Mordi, 2020, Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure: the RECEDE-CHF trial, Circulation, 142, 1713, 10.1161/CIRCULATIONAHA.120.048739 Boorsma, 2020, Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment, Nat Rev Cardiol, 17, 641, 10.1038/s41569-020-0379-7 Lambers Heerspink, 2013, Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes, Diabetes Obes Metab, 15, 853, 10.1111/dom.12127 Dekkers, 2019, Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes, Diabetes Obes Metab, 21, 2667, 10.1111/dom.13855 Sha, 2014, Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus, Diabetes Obes Metab, 16, 1087, 10.1111/dom.12322 Wanner, 2016, Empagliflozin and progression of kidney disease in type 2 diabetes, N Engl J Med, 375, 323, 10.1056/NEJMoa1515920 Mosenzon, 2019, Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial, Lancet Diabetes Endocrinol, 7, 606, 10.1016/S2213-8587(19)30180-9 van Bommel, 2020, The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial, Kidney Int, 97, 202, 10.1016/j.kint.2019.09.013 Cherney, 2014, Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus, Circulation, 129, 587, 10.1161/CIRCULATIONAHA.113.005081 Cherney, 2020, Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial, Lancet Diabetes Endocrinol, 8, 582, 10.1016/S2213-8587(20)30162-5 Jensen, 2019, Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF), Trials, 20, 374, 10.1186/s13063-019-3474-5 Jensen, 2020, Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: a double-blinded, randomized, and placebo-controlled trial, Am Heart J, 228, 47, 10.1016/j.ahj.2020.07.011 Omar, 2020, Effect of empagliflozin on hemodynamics in patients with heart failure and reduced ejection fraction, J Am Coll Cardiol, 76, 2740, 10.1016/j.jacc.2020.10.005 Christensen, 1986, Determination of 99mTc-DTPA clearance by a single plasma sample method, Clin Physiol, 6, 579, 10.1111/j.1475-097X.1986.tb00790.x Duarte, 2015, Prognostic value of estimated plasma volume in heart failure, JACC Heart Fail, 3, 886, 10.1016/j.jchf.2015.06.014 Damman, 2020, Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF), Eur J Heart Fail, 22, 713, 10.1002/ejhf.1713 Clark, 2014, Worsening renal function during renin-angiotensin-aldosterone system inhibitor initiation and long-term outcomes in patients with left ventricular systolic dysfunction, Eur J Heart Fail, 16, 41, 10.1002/ejhf.13 Mazer, 2020, Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease, Circulation, 141, 704, 10.1161/CIRCULATIONAHA.119.044235 Schrier, 2008, Blood urea nitrogen and serum creatinine: not married in heart failure, Circ Heart Fail, 1, 2, 10.1161/CIRCHEARTFAILURE.108.770834 Yale, 2013, Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease, Diabetes Obes Metab, 15, 463, 10.1111/dom.12090 Lytvyn, 2015, Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus, Am J Physiol Renal Physiol, 308, F77, 10.1152/ajprenal.00555.2014 Bailey, 2019, Uric acid and the cardio-renal effects of SGLT2 inhibitors, Diabetes Obes Metab, 21, 1291, 10.1111/dom.13670 Huang, 2014, Uric acid and risk of heart failure: a systematic review and meta-analysis, Eur J Heart Fail, 16, 15, 10.1093/eurjhf/hft132 Zhao, 2018, Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials, Diabetes Obes Metab, 20, 458, 10.1111/dom.13101 Jackson, 2009, Albuminuria in chronic heart failure: prevalence and prognostic importance, Lancet, 374, 543, 10.1016/S0140-6736(09)61378-7